MedicineWorld.Org
Your gateway to the world of medicine
Home
News
Cancer News
About Us
Cancer
Health Professionals
Patients and public
Contact Us
Disclaimer

Medicineworld.org: Researchers link enzyme to breast cancer malignancy

Back to breast cancer blog Blogs list Cancer blog  


Subscribe To Breast Cancer Blog RSS Feed  RSS content feed What is RSS feed?

Researchers link enzyme to breast cancer malignancy




This release is available in French.
McGill University scientists have uncovered the crucial role played by the enzyme focal adhesion kinase (FAK) in the onset of breast cancer. The research, led by Dr. William Muller along with colleagues from McGill and the Beatson Institute for Cancer Research in Scotland was published the week of November 26 in the Proceedings of the National Academy of Sciences (PNAS). The study's first author is Dr. Hicham Lahlou, a post-doctoral fellow in Dr. Muller's lab.



Researchers link enzyme to breast cancer malignancy

Using transgenic mice with pre-existing cancers, the McGill team was able to disable the function of FAK in the mammary gland. "When we did that, we basically blocked tumour progression in our mouse model," said Dr. Muller, Professor of Biochemistry at McGill, Canada Research Chair in Molecular Oncology and a researcher with the Molecular Oncology Group at the McGill University Health Centre (MUHC). "This shows that FAK, which was already associated with tumour growth in skin carcinomas, is very critical for tumour progression from a pre-cancerous to a cancerous state in the mammary tumour system."

Dr. Muller and his team made a similar breakthrough with an earlier discovery in 2004, when they showed that the protein beta1-integrin was similarly critical in the initiation of tumour growth and development of breast cancer in genetically engineered mice. Likewise, when this gene was blocked, malignant tumours ceased to grow. The current discovery about FAK is an exciting sequel to the earlier research, says Dr. Muller, because, unlike beta1-integrin, kinase enzymes are eminently "druggable" with current technology.

Dr. Muller cautions that this study like the Beatson Institute's earlier research linking FAK to tumour progression in skin carcinomas is still preliminary. "However, developing an FAK inhibitor would certainly add another weapon to the arsenal for dealing with breast cancer," he said.


Posted by: Janet    Source




Did you know?
This release is available in French. McGill University scientists have uncovered the crucial role played by the enzyme focal adhesion kinase (FAK) in the onset of breast cancer. The research, led by Dr. William Muller along with colleagues from McGill and the Beatson Institute for Cancer Research in Scotland was published the week of November 26 in the Proceedings of the National Academy of Sciences (PNAS). The study's first author is Dr. Hicham Lahlou, a post-doctoral fellow in Dr. Muller's lab.

Medicineworld.org: Researchers link enzyme to breast cancer malignancy

BREAST CANCER MAIN| Home| Breast cancer news| Common terms| Breast cancer treatment| Breast cancer treatment by stage| Mammogram and breast cancer screening| Surgical treatment of breast cancer| Chemotherapy of breast cancer| Chemo drugs used in breast cancer| Doxorubicin| Cyclophosphamide| Methotrexate| Hormonal therapy of breast cancer| Radiation therapy of breast cancer| Monoclonal therapy| High dose chemotherapy for breast cancer| Recurrent breast cancer| Bisphosphonates and breast cancer| Pregnancy and breast cancer| Risk factors for breast cancer| Risk details| My risk| Comprehensive breast cancer information| Breast cancer statistics| African Americans and breast cancer| Ashkenazi and breast cancer| Asians| Hispanic| Men| Native Americans| Older women and breast cancer| Younger women| Pregnant women and breast cancer| BRCA|

Copyright statement
The contents of this web page are protected. Legal action may follow for reproduction of materials without permission.